Lifecore Biomedical
LFCR
75 hedge funds and large institutions have $358M invested in Lifecore Biomedical in 2023 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 10 increasing their positions, 28 reducing their positions, and 26 closing their positions.
196% more capital invested
Capital invested by funds: $121M → $358M (+$237M)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
34% more call options, than puts
Call options by funds: $5.8M | Put options by funds: $4.32M
9% less funds holding
Funds holding: 82 → 75 (-7)
9.23% less ownership
Funds ownership: 74.74% → 65.51% (-9.2%)
27% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 26
64% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GRIM
Greenhaven Road Investment Management
Greenwich,
Connecticut
|
+$5.3M |
| 2 |
Millennium Management
New York
|
+$2.29M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.67M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$776K |
| 5 |
Jane Street
New York
|
+$580K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$8.35M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.26M |
| 3 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$1.89M |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$1.79M |
| 5 |
CSC
Cove Street Capital
El Segundo,
California
|
-$1.62M |
LFCR Hedge Fund Activity: Q2 2023 in Review
75 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q2 2023, worth a combined $358M — up 196% from $121M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of LFCR and 19 opened new positions — a net loss of 7 holders — while 28 trimmed existing stakes and 10 added.
The largest buyer was Greenhaven Road Investment Management, adding an estimated $5.3M. The largest seller was BlackRock, cutting an estimated $8.35M.
- 75 institutional investors held Lifecore Biomedical (LFCR) as of Q2 2023, down from 82 in Q1 2023.
- Funds reported $358M of Lifecore Biomedical stock for Q2 2023, up 196% quarter-over-quarter.
- 19 funds opened new Lifecore Biomedical positions in Q2 2023 and 26 closed out, a net change of -7 holders.
- The largest Lifecore Biomedical buyer in Q2 2023 was Greenhaven Road Investment Management, an estimated $5.3M added.
- The largest Lifecore Biomedical seller in Q2 2023 was BlackRock, an estimated $8.35M sold.
Based on aggregated 13F filings for Q2 2023.